Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
Portfolio Pulse from Vandana Singh
Incyte Corporation has announced positive topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with atopic dermatitis (AD). The study met its primary endpoint, showing significantly more patients treated with ruxolitinib cream achieved Investigator's Global Assessment Treatment Success than those treated with a non-medicated cream. The safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed. The long-term safety portion of the study will continue as planned.
July 12, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incyte's ruxolitinib cream has shown positive results in a Phase 3 study for children with atopic dermatitis, meeting its primary endpoint. This could potentially lead to an increase in the company's stock value, despite a premarket drop.
The positive results from the Phase 3 study of Incyte's ruxolitinib cream indicate a potential new market for the drug, which is already approved for other skin conditions. This could lead to increased revenues for the company, positively impacting its stock value. However, the stock is down 1.51% in premarket trading, which may be due to other factors not mentioned in the article.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100